Pemetrexed maintenance therapy prolongs survival in nonsquamous NSCLC
Pemetrexed maintenance therapy offers a survival benefit over placebo and is well tolerated in patients with advanced nonsquamous non-small-cell lung cancer, final results of the PARAMOUNT trial show.
No comments:
Post a Comment